Organization · Venture Capital
The Mission Fund
The Mission Fund is a London-based venture fund focused on investing in pre-proof-of-concept biotech companies developing potentially curative therapies, particularly in cancer, mental health, and aging-related conditions.
Overview
What The Mission Fund does
What The Mission Fund is
The Mission Fund is a London-based venture fund focused on investing in pre-proof-of-concept biotech companies developing potentially curative therapies, particularly in cancer, mental health, and aging-related conditions.
How it participates in the startup ecosystem
The current public profile supports funder capabilities. Each capability below is shown separately so organization identity and role-specific information do not get conflated.
Operational profile
Organization status and context
Organization status describes the entity itself. Funding and program availability appear within the relevant capability profile.
- Operational status
- Active
- Organization type
- Venture Capital
- Structured capabilities
- Funder
- Last reviewed
- May 1, 2026
Official channels
Find The Mission Fund elsewhere
Open the official website or a supported primary organization account.
Capability profile
The Mission Fund as a funder
Investment thesis
The Mission Fund targets the funding gap before expensive proof-of-concept data exists, providing capital for critical studies in potentially curative therapies.
Focus narrative
The Mission Fund invests in biotech companies developing potentially curative therapies, particularly in the areas of solid tumors, central nervous system (CNS) related indications (especially mental health), and aging-related conditions (longevity). The fund focuses on providing financial support for critical proof-of-concept studies to help these companies advance their therapeutic approaches.
Value beyond capital
The Mission Fund provides not only financial support but also access to a network of experts who assist in selecting technologies and designing experiments, thereby enhancing the likelihood of success for portfolio companies.
Terms and economics
- Typical check
- $312,500–$625,000
- Sweet spot
- $500,000
Focus and fit
- Stages
- Pre-seed
- Regions
- Uk · Europe · Eu
Availability
- Currently deploying
- Yes
Portfolio and track record
- Recorded portfolio count
- 3
Portfolio context
Notable portfolio companies include Re-wire Therapeutics, which is developing a patent-pending timed-release combination approach for administering 5-MeO-DMT; Zonula, working on a patented small molecule inhibiting N-cadherin mediated cell-cell adhesion for cancer-related therapeutic resistance; and NEOBE Therapeutics, focused on improving immune checkpoint inhibitor success in solid tumors.
Common questions
What to know about The Mission Fund
Upseed classifies The Mission Fund under the Venture Capital organization type. Its current public profile includes funder capabilities.
Source and update disclosure
Know what this page is based on
Source basis
Public organization and program material, official websites, and structured Upseed records.
Last reviewed
May 1, 2026
Known limits
Capability profiles appear only when a structured public profile also contains decision-useful role evidence. Terms and availability can change.
Upseed is an independent guide. It is not affiliated with or endorsed by the organization described on this page.